Speaker Profile

Ph.D., VP, Research, Biological Dynamics

JP leads R&D for Biological Dynamics’ proprietary Verita™ isolation platform, which enables the use of extracellular vesicle (EV)-based protein biomarkers for early cancer detection, as well as neurodegenerative and infectious diseases. His team is at the forefront of EV-based liquid biopsy technology, including the discovery of new applications and biomarkers enabled by AC Electrokinetics (ACE). He has been instrumental in developing Biological Dynamics’ technology demonstrating the capability of ACE to identify cell-free biomarkers. His most recent publication showcases how EV-protein markers can be used to detect stage I and stage II pancreatic, ovarian, and bladder cancers. Prior to joining Biological Dynamics, JP completed postdoctoral assignments for the United States Department of Energy’s Oak Ridge National Laboratory and the École Polytechnique Fédérale de Lausanne in Switzerland. JP has authored numerous publications in the fields of biocompatible, functional surfaces. He holds a PhD in Chemical & Biomolecular Engineering from Clemson University.

Liquid Biopsy Showcase:
Biological Dynamics

Biological Dynamics, Inc. is a healthcare company committed to improving global health outcomes by detecting diseases at their earliest stages. The company's proprietary platform simplifies access to native-state biomarkers and nanoparticles, enabling differentiated multiomics applications.

Exosome Classifier For Early-Stage Cancer Detection
Biological Dynamics is advancing early cancer detection by leveraging its Verita™ platform to capture and analyze exosomes from early-stage (I/II) cancer patient samples. Analysis of exosomal biomarkers enables highly sensitive and specific cancer detection, potentially allowing earlier cancer intervention.

 Session Abstract – PMWC 2022 Silicon Valley

The PMWC 2022 Liquid Biopsy Showcase will provide a 15-minute time slot for selected liquid biopsy companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies that advance the development of screening tests for oncology, immunotherapy, and other areas, based on detection and identification of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating RNA, circulating microRNAs, or extracellular vesicle (exosomes).